Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 8/20 | 0.69 |
| ▸ | CA2 | P00918 | 8/20 | 0.69 |
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | CA12 | O43570 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11887649 | 0.85 | CA1 (0.77) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL13401865 | 0.84 | CA1 (0.86) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL6046379 | 0.84 | MEN1 (0.90) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL11807861 | 0.83 | MEN1 (0.87) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL29818055 | 0.83 | RAB9A (1.00) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL15679860 | 0.82 | NPC1 (0.77) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL19334404 | 0.81 | NPC1 (0.68) | NPC1RAB9ACA1CA2CA9 | |
| SCHEMBL15678779 | 0.80 | NPC1 (0.70) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL15678774 | 0.80 | NPC1 (0.70) | NPC1RAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL29818032 | 0.79 | RAB9A (0.77) | NPC1RAB9AMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445537-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | STC.UNM (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | NPC1 3302/4885RAB9A 3595/4885CA1 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.